81 results about "Colon inflammation" patented technology

The present invention discloses a Lactobacillus plantarum and its application in the preparation of functional preparations for preventing and treating inflammatory bowel disease, as well as antioxidant, anti-inflammatory and antibacterial functions. It has excellent ability to scavenge reactive oxygen species, as well as good probiotic characteristics such as acid tolerance, bile salt tolerance, hydrophobicity, self-aggregation ability and inhibition of common human pathogenic bacteria. At the same time, it can improve intestinal inflammation, has a preventive and therapeutic effect on inflammatory bowel disease, and has high biological safety. It can be used as a probiotic preparation to relieve inflammatory bowel disease, improve intestinal mucosal damage and colon inflammation, providing a new strategy for the prevention and treatment of inflammatory bowel disease and having potential clinical application prospects.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

The invention belongs to the technical field of drug delivery, and particularly relates to a multi-response colitis disease targeting hydrogel microsphere as well as a preparation method and application thereof. The hydrogel microsphere comprises a calcium ion cross-linked sodium alginate microsphere and HA-Cys / Cur NPs which is encapsulated in the calcium ion cross-linked sodium alginate microsphere, the preparation method comprises the following steps: self-assembling cysteine ethyl ester modified hyaluronic acid and curcumin to form nano-particles, encapsulating HA-Cys / Cur NPs into sodium alginate microspheres by an emulsification method, and carrying out calcium ion crosslinking, so as to obtain the hydrogel. The hydrogel microspheres have pH and GSH response characteristics and hyaluronic acid-mediated active targeting capability, are stable in a gastric acid environment, are accurately released at a colon part and target macrophages at an inflammation part, and NPs disconnects disulfide bonds and releases curcumin in an intracellular high GSH environment, so that synergistic treatment of anti-inflammation, anti-oxidation and intestinal mucosa repair is realized, and the curative effect is good. The medicine has a good application prospect in treatment of ulcerative colitis.

The invention relates to hyaluronic acid-based nanogel with intestinal targeting and inflammation responsiveness as well as a preparation method and application of the hyaluronic acid-based nanogel, and discloses multifunctional composite nanogel based on hyaluronic acid as well as a preparation method and application of the multifunctional composite nanogel. The preparation method comprises the following steps: loading galangin into bovine serum albumin to prepare BSA-GA nanoparticles with antioxidant and anti-inflammatory activity; 2, synthesizing a multifunctional molecule Se-MHA which is targeted to M2 macrophages and responds to ROS degradation on the basis of hyaluronic acid; 3, BSA-GA nano-particles with the same solution concentration are used as anti-inflammatory functional components to be mixed with Se-MHA to prepare Se-MHA / BG nano-gel, model probiotics are subjected to single-cell modification, probiotic-loaded nano-gel EcN-Se-MHA / BG is prepared, the nano-gel has specific binding and responding capacity on the colitis disease part, colonization of EcN on the colon part is promoted, and the anti-inflammatory effect is achieved. The IBD disease is effectively relieved.

The invention provides a preparation method and application of an intestinal adhesion delivery system based on pea 2S albumin. The intestinal adhesion delivery system is a protein-polyphenol compound generated by covalent binding of quinone obtained by oxidizing polyphenol through periodate resin and pea 2S albumin. According to the intestinal adhesion delivery system, cysteine-rich pea 2S albumin is used as a delivery carrier, polyphenol bioactive substances are loaded on the cysteine-rich pea 2S albumin, release of functional components in the digestion process is effectively delayed, and the gastrointestinal stability is improved. The composition is applied to the fields of inflammatory bowel diseases and intestinal infection, can target the diseased region of colitis, and effectively relieves the symptoms of colitis by enhancing the barrier function of intestinal mucosa, regulating intestinal flora and inhibiting inflammatory response. The intestinal adhesion delivery system can also deliver other bioactive substances, is applied to the fields of biological science, functional food and the like, and has good development potential.

The invention discloses a Bifidobacterium bifidum CCFM1424 capable of relieving senescence and an application of the Bifidobacterium bifidum CCFM1424, and belongs to the technical field of microorganisms. The bifidobacterium bifidum CCFM1424 disclosed by the invention can be used for effectively relieving cognitive defects of aged mice, improving the oxidation resistance (SOD, CAT, MDA and GSH-Px) of the brain and the liver, reducing the levels of proinflammatory factors TNF-alpha, IL-1beta and IL-6 in serum and relieving colitis. In addition, the intervention of the bifidobacterium bifidum CCFM1424 can maintain muscle health, and can improve the change of intestinal flora and intestinal metabolites related to aging. According to the bifidobacterium bifidum, the application range of the bifidobacterium bifidum as probiotics is expanded, and the bifidobacterium bifidum has a huge application prospect in the aspect of relieving senescence.

The invention relates to the technical field of hyaluronic acid derivatives and nano drug delivery systems, in particular to a lipoic acid grafted hyaluronic acid derivative, a preparation method and application, and provides a lipoic acid grafted hyaluronic acid derivative with a structure that lipoic acid is grafted with hyaluronic acid through a thioketal bond. A lipoic acid grafted hyaluronic acid derivative loaded IAA drug delivery system is constructed, can be gathered at a colitis disease part through intravenous injection, and is actively absorbed by cells by virtue of the affinity effect of hyaluronic acid in a lipoic acid grafted hyaluronic acid derivative structure on CD44 receptors on the surfaces of inflammatory cells; according to the present invention, with the application of the IAA in the cell, the responsive structure degradation occurs in the intracellular high oxidative stress environment, and the IAA is delivered into the cell in the positioning manner, such that the IAA inhibits the inflammation generation by activating the AhR and the downstream oxidative stress and inflammatory reaction related pathway so as to promote the mucous membrane repair, and the problem that the colitis treatment drug cannot accurately act on the focus in the prior art is solved.

The invention discloses a construction method and application of a probiotic engineering bacterium EcNpAm targeting animal intestinal tracts and improving inflammation. According to the present invention, the heterologous expression of the immunomodulatory protein Amuc1100 is successfully achieved through the gene engineering technology by using the Escherichia coli Niss1917 (EcN) as the host and using the anaerobic inducible plasmid pnirBMisL as the expression vector, and the novel engineering bacterium EcNpAm suitable for the animal intestinal anaerobic environment is constructed; furthermore, the expression efficiency of the target protein is represented by fusion expression of green fluorescent protein (GFP). The engineering bacterium is applied to prevention and treatment of animal intestinal inflammation, and successfully realizes targeted delivery of therapeutic protein to intestinal tracts of mice. Experiments show that EcNpAm can effectively relieve typical symptoms such as weight loss, colon shortening, pathological injury, colitis and the like of mice induced by dextran sodium sulfate (DSS) and protect integrity and functions of an intestinal barrier structure.

The invention discloses a folic acid modified active oxygen response type sodium alginate nano-carrier and application thereof, and the preparation method comprises the following steps: firstly synthesizing-Se-Se-FA: stirring dicyclohexylcarbodiimide, 4-dimethylaminopyridine, dimethyl sulfoxide / pyridine, a double-selenium fragment and folic acid at room temperature for 18-22 hours in an argon environment; and carrying out acetone precipitation, centrifugation, washing, rotary evaporation concentration and freeze-drying. The preparation method comprises the following steps: preparing an ALG-Se-FA carrier, stirring sodium alginate, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride and hydroxysuccinimide in a 2-morpholinoethanesulfonic acid buffer solution, adding DMSO, dissolving a double-selenium fragment and a-Se-Se-FA fragment in DMSO and deionized water, adding the dissolved double-selenium fragment and-Se-Se-FA fragment into a system, stirring, dialyzing, and freeze-drying to obtain the product. According to the carrier, a double-selenium bond ROS response unit and folic acid targeting molecules are introduced through covalent bonds, astaxanthin can be efficiently entrapped and protected, and after the carrier is stable in gastrointestinal environment and reaches a colitis disease part, high ROS level can be responded, and intelligent drug slow release is achieved through folic acid receptor targeting.

The invention discloses a piglet intestinal health targeting probiotic engineering bacterium compound as well as preparation and application thereof. The compound is FP (at) EcN-pnirNKL, wherein a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin, and a) the EcN-pnirNKL is an engineering strain which is constructed by taking escherichia coli Niss1917 (EcN) as a host and carrying a recombinant plasmid pnirBMisL-NK-Lysin; b) the recombinant plasmid pnirBMisL-NK-Lysin comprises an NK-Lysin gene optimized by a codon, and the NK-Lysin gene is integrated into the anaerobic inducible plasmid pnirBMisL through homologous recombination; c) the FP is a composite nano-particle which takes nano mesoporous silica (MSN) as a core and is formed by crosslinking fucoidin and rhodiola rosea polysaccharide; and d) the FP (at) EcN-pnirNKL is an oral delivery system which is formed by encapsulating the engineering bacterium EcN-pnirNKL in the FP nano particles. When the compound is applied to prevention and treatment of stress response of weaned piglets, various typical symptoms, including weight loss, colon shortening, histopathological injury and colitis disease response, of the piglets induced by dextran sodium sulfate can be remarkably relieved, and meanwhile, the integrity and functions of an intestinal barrier structure are effectively protected.

The invention discloses a composition for synergistically regulating intestinal flora and application thereof. The composition comprises the following components in parts by weight: 10-80 parts of a cordyceps militaris extract, 2-40 parts of quercetin, 5-50 parts of prebiotics and 5-80 parts of nucleotide. The compositions provided by the invention supplement each other, have a synergistic effect, are compounded according to a scientific proportion, can improve the diversity of intestinal microorganisms of mice and the abundance of species, and can significantly improve intestinal inflammation symptoms in a mouse colitis model.

The invention discloses a medicine compound for treating inflammatory diseases of colitis. The medicine compound is formed by compounding acetylated gastrodia elata gum and oxsalazine, the mass ratio of the acetylated gastrodia elata gum to the oxsalazine is (50-150): 20; the acetylated gastrodia elata gum is prepared by reacting a colloidal white solid obtained by water extraction and alcohol precipitation of gastrodia elata with acetic anhydride. According to the medicine compound, the gastrodia elata colloid polysaccharide with specific molecular weight is acetylated and subjected to porous treatment and then compounded with the oxsalazine according to a specific ratio, so that the medicine compound can be continuously released at a colon focus part, has colon targeting and slow release effects, can remarkably reduce oxidative stress of colon cells, and can be used for treating the colon focus part. The effect is better than that of any single gastrodia elata colloid polysaccharide and oxalazine, the synergistic effect is generated in the aspect of protecting colon cells, and the gastrodia elata colloid polysaccharide and oxalazine composition has actual popularization and application value.

The invention discloses an ROS responsive hydrogel delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The hydrogel delivery system is prepared from sulfur-doped ginger carbon dots (SGCDs) and an ROS (reactive oxygen species) responsive sulfhydrylation hyaluronic acid (HS) hydrogel matrix, the SGCDs have excellent antioxidant and anti-inflammatory activity, and can be used for clearing ROS and simulating SOD and CAT enzyme functions; the HS hydrogel matrix triggers gelling in an inflammation part high ROS environment, and targeted drug release and colitis part retention are achieved. Through the synergistic effect of the SGCDs and the HS hydrogel matrix, the delivery system can efficiently remove ROS, promote polarization of macrophages from M1 type to M2 type, up-regulate an anti-inflammatory factor IL-10, down-regulate proinflammatory factors TNF-alpha, IL-1beta and IL-6, repair Occludin and remodel the intestinal flora homeostasis.

The invention discloses a pharmaceutical composition for improving or treating ulcerative colitis as well as a preparation method and application thereof. The pharmaceutical composition is prepared from the following raw materials: radix puerariae, radix scutellariae, rhizoma coptidis, honey-fried licorice root, baked ginger and humifuse euphorbia herb. Research on a classic famous prescription, namely, the radix puerariae, radix scutellariae and ligation decoction, for treating damp-heat downward benefiting discovers that the modified prescription of the radix puerariae, radix scutellariae and ligation decoction has a good treatment effect on ulcerative colitis. According to the invention, reverse and assistant traditional Chinese medicines capable of warming middle energizer and dysentery are added into the group medicines capable of clearing heat and promoting diuresis, so that the modified prescription of the radix puerariae, radix scutellariae and lianghua decoction is formed through improvement, and research shows that the modified prescription can obviously improve the colitis symptom of acute colitis. In addition, the preparation method of the pharmaceutical composition also has the characteristics of rapidness, simplicity, convenience and easiness in operation.

The present application relates to the technical field of biological medicine engineering, and provides application of RBFOX2 inhibitor in treatment of inflammatory bowel disease, and particularly relates to the role of interfering RNA or antisense oligonucleotide or recombinant expression vector targeting RBFOX2 coding sequence in preparation of products for treating colitis and its related symptoms and / or other complications, and also relates to corresponding recombinant vectors or pharmaceutical compositions. The RBFOX2 inhibitor can effectively reduce the level of proinflammatory cytokines, inhibit the activation of macrophages, has effective application value in relieving and treating colonic inflammation and other symptoms and / or other complications of inflammatory bowel disease, provides a new target for treatment of inflammatory bowel disease, and has wide clinical application prospect.

The invention discloses mucoprotein nano-selenium gas motor hydrogel as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The preparation method of the mucoprotein nano-selenium gas motor hydrogel comprises the following steps: adding a carbonyl compound and selenite into an emulsifier solution, and adding a reducing agent for mixing reaction to obtain a nano-selenium gas motor, oxidized mucoprotein and the nano-selenium gas motor are mixed, then a cross-linking agent is added, the oxidized mucoprotein is subjected to a cross-linking reaction to form gel, and the mucoprotein nano-selenium gas motor hydrogel is obtained. The mucoprotein nano-selenium gas motor hydrogel is constructed by wrapping a gas motor into a mucoprotein hydrogel delivery system, the mucoprotein nano-selenium gas motor hydrogel can be specifically delivered to a colitis disease part through rectal administration, and meanwhile, the safe and controllable release and mucous membrane protection effects of the nano-selenium gas motor are realized; therefore, a new thought is provided for treating enteritis.

The invention relates to an application of an active peptide LLAPP in preparation of medicines for preventing and / or treating ulcerative colitis, cerebral ischemia and / or myocardial ischemia. According to the present invention, the LLAPP administration UC mouse animal experiment and the lipopolysaccharide (LPS) stimulation RAW264.7 cell experiment verify that the LLAPP can effectively relieve the ulcerative colitis, the cerebral ischemia and the myocardial ischemia symptoms, can be used as the ulcerative colitis, the cerebral ischemia and the myocardial ischemia treatment drug, can significantly improve the colitis symptoms, can alleviate the cerebral ischemia and myocardial ischemia injury, and can be used as the drug for treating the ulcerative colitis, the cerebral ischemia and the myocardial ischemia injury. Good development and application prospects are realized.

The invention provides porous fiber composite microbial microspheres and application thereof, and belongs to the technical field of probiotic preparations. The porous fiber composite microbial microsphere has a porous structure skeleton composed of A-CMC and ADH-HA, and probiotics loaded by the skeleton, and an ADH-HA film wrapping the probiotics is attached to the surface of the skeleton of the microsphere. The microspheres are obtained by shearing a precursor solution of the composite fiber microspheres into liquid drops with the diameter of 200-600 microns and freeze-drying the liquid drops. Wherein the composite fiber microsphere precursor solution is prepared by mixing an A-CMC suspension solution with the concentration of 0.9 to 1.3 percent, an ADH-HA solution with the concentration of 0.1 to 0.9 percent and probiotics treated by glycerol. The microsphere is good in cell compatibility, actively adheres to the wall in intestinal juice, has specific adhesiveness to a colitis disease part, can realize targeted therapy, and can ensure that enough active probiotics reach the colitis disease part.

The invention relates to the technical field of intestinal inflammation disease prevention and treatment, in particular to a polypeptide for treating ulcerative colitis. The polypeptide provided by the invention is an active heptapeptide derived from natural protein, and has a clear chemical structure and a repeatable preparation process. Research results show that the polypeptide can significantly improve symptoms of mouse ulcerative colitis induced by dextran sodium sulfate (DSS), including weight loss reduction, disease activity index (DAI) reduction, colon length recovery, colon tissue pathological damage improvement and inflammation-related signal pathway inhibition, so that the improvement effect of the polypeptide on intestinal inflammation is verified. The polypeptide is prepared into a pharmaceutical composition or health-care food, so that the comprehensive effects of considering prevention and treatment and simultaneously improving inflammation and repairing barriers can be realized, and a new strategy and a material basis are provided for preventing and treating ulcerative colitis and other intestinal inflammatory diseases.

The invention discloses an application of lysinibacillus fusiformis in preparation of a medicine for preventing and treating constipation, and particularly, the lysinibacillus fusiformis can promote digestion, dredge intestines and moisten bowel and play a role in preventing constipation; the traditional Chinese medicine composition also can inhibit weight loss and colon shortening, increase the water content of excrement, enhance the intestinal transport capacity and relieve colitis injury caused by constipation, realizes treatment of constipation, and has a good application prospect.

This invention belongs to the field of biomedicine, specifically relating to small interfering RNA (sRNA) targeting the TNF-α gene; it includes a sense strand and an antisense strand; the sense strand and / or the antisense strand has a length ranging from 19 to 25 nucleotides, and the antisense strand is inversely complementary to a segment on the target gene. Furthermore, it achieves drug delivery of the small interfering RNA through a specific target gene, enabling precise drug targeting at the site of colonic inflammation, enhancing the therapeutic effect of IBD without causing systemic immunosuppression, thus providing a more precise and efficient gene regulation tool.

The invention discloses a manganese-doped carbon dot and a preparation method and application thereof.The preparation method comprises the steps that citric acid is dissolved in deionized water, then MnCl2. 4H2O, ethanediamine and N-acetylcysteine are sequentially added and fully dissolved, and a hydrothermal reaction is conducted to obtain the small-particle-shaped manganese-doped carbon dot. According to the invention, the inorganic substance MnCl2. 4H2O which is widely anti-inflammatory and anti-oxidation is utilized to participate in the preparation of the carbon dots through a simple hydrothermal synthesis method, and the obtained manganese-doped carbon dots have the advantages of excellent multi-enzyme activity, good biocompatibility and the like, and have good application prospects in the aspects of inflammatory enteritis, colitis recovery and the like.

The invention discloses breast milk-derived bifidobacterium breve for relieving inflammatory bowel diseases and application of the breast milk-derived bifidobacterium breve. The bifidobacterium breve is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation date is November 13, 2024, and the preservation number is CGMCC No. 32608. The bifidobacterium breve has the function of regulating the immunity of the intestinal tract, can effectively enhance the barrier of the intestinal tract, and plays a positive role in relieving the symptoms of colitis; compared with a traditional medicine for treating colitis, a medicine or a probiotic preparation prepared from the bifidobacterium breve has certain advantages and has a wide application prospect.

The present application relates to the technical field of microorganism, in particular to a leuconostoc lactis with good probiotic characteristics and application thereof in preparation of drugs for preventing and treating inflammatory bowel disease, and the leuconostoc lactis (Leuconostoc lactis) LL271 provided by the present application is preserved in China General Microbiological Culture Collection Center, and the preservation number is CGMCC No. 25974.The strain has good acid tolerance, bile salt tolerance, self-aggregation ability, hydrophobicity and other probiotic characteristics such as the ability to inhibit common human pathogenic microorganisms; meanwhile, the strain can improve intestinal inflammation, has prevention and treatment effects on inflammatory bowel disease, has high biological safety, can be used as probiotic preparation for relieving inflammatory bowel disease, improving intestinal mucosal injury and colon inflammation, provides a new strategy for preventing and treating inflammatory bowel disease, and has a potential clinical application prospect.

The invention relates to an inflammatory environment induced overexpression 1L-10 engineered macrophage and a construction method and application thereof, and belongs to the field of biomedicine.The construction method includes the steps that a recombinant plasmid for expressing IL-10 is constructed with a genetic engineering method, and an RAW264.7 macrophage is jointly transfected with the constructed recombinant plasmid for expressing IL-10 and a Cas9 plasmid, so that the engineering macrophage with the inflammatory environment induced overexpression 1L-10 is obtained, and the engineering macrophage with the inflammatory environment induced overexpression 1L-10 is obtained. According to the method, the IL-10 gene is used for replacing the position of the IL-1 gene in the RAW264.7 macrophage, so that the RAW264.7 macrophage can express IL-10 under the induction of an inflammatory environment, the constructed engineered macrophage is injected into the abdominal cavity of a colitis model mouse in an intraperitoneal injection manner, the macrophage is positioned to the colitis disease part and secretes an anti-inflammatory cytokine IL-10 due to the inflammatory chemotaxis of the macrophage, and the anti-inflammatory cytokine IL-10 is obtained. The effect of relieving intestinal inflammation is achieved. According to the invention, the development of ulcerative colitis treatment technology is facilitated, and the application of a macrophage-based cell treatment method in treatment of digestive system diseases is promoted.

The invention discloses a polyphenol-calcium phosphate-hyaluronic acid multifunctional probiotic delivery carrier with an adjustable structure and a preparation method of the polyphenol-calcium phosphate-hyaluronic acid multifunctional probiotic delivery carrier. The carrier is constructed by regulating calcium phosphate mineralization through polyphenol to form a flower-like structure and then adsorbing hyaluronic acid. The preparation method comprises the following steps: (1) preparing nanoflowers from polyphenol chelated calcium phosphate; (2) in-situ packaging of probiotics by the nanoflowers; and (3) coating the probiotic carrier with hyaluronic acid. The preparation method is simple in process and mild in condition, the prepared probiotic packaging body is excellent in biocompatibility, not only can improve gastrointestinal fluid environment tolerance, but also has the capabilities of active oxygen removal, inflammation targeting and intestinal colonization, and by synergistically reducing colitis, relieving tissue damage, repairing intestinal mucosal barrier and restoring intestinal flora balance, the intestinal tract intestinal colonization effect is improved. A new strategy is provided for the treatment of the inflammatory bowel disease.

The application belongs to the technical field of microorganisms, and discloses Lactobacillus fermentum (L.f) LFSJ001 and application thereof in preparation of products for preventing or treating ulcerative colitis. The Lactobacillus fermentum LFSJ001 is independently isolated and identified. It is found through the use of DSS to construct a mouse colitis model that the Lactobacillus fermentum LFSJ001 combined with 5-Aminosalicylic Acid (5-ASA) can enhance the improvement of 5-ASA on the symptoms of colitis, including multiple indexes such as disease activity index, colon injury, and spleen index. It can be seen that the Lactobacillus fermentum LFSJ001 can be used as a combined drug of 5-ASA, enhance the efficacy of 5-ASA, inhibit the occurrence and development of ulcerative colitis, and improve the intestinal barrier. The application provides a new diagnosis and treatment direction and strategy for the prevention and treatment of ulcerative colitis.

The application discloses curcumin nanoparticles with improved ulcerative colitis efficacy and a preparation method thereof. The application aims to solve the technical bottleneck that curcumin, an anti-inflammatory efficacy component, has poor stability and is difficult to reach the colon site, and provides a preparation method of curcumin nanoparticles with improved ulcerative colitis efficacy based on alkaline pH-mediated assembly and with colon-targeted delivery effect. The nanoparticles are all prepared from food raw materials, and the preparation process is simple, mild, controllable and easy to industrialize, does not involve any organic solvents and chemical reagents, and realizes efficient embedding of curcumin (the embedding rate is as high as 91.4%). The curcumin nanoparticles provided by the application can effectively alleviate the symptoms of dextran sodium sulfate-induced ulcerative colitis in mice in a dose-dependent manner, including improving body weight loss and colon shortening, and significantly inhibiting the expression of pro-inflammatory factors, and the effect is better than that of a conventional positive drug (mesalamine).

The invention provides application of a five-membered heterocycle substituted styrene derivative in preparation of a medicine for treating ulcerative colitis and / or improving intestinal barrier function and the medicine. The five-membered heterocycle substituted styrene derivative disclosed by the invention not only can be used for remarkably relieving symptoms of mouse ulcerative colitis (UC) induced by dextran sodium sulfate (DSS), but also is safe and free from toxic and side effects. The invention also verifies that the five-membered heterocycle substituted styrene derivative has an anti-inflammatory effect, can improve the barrier function of the intestinal tract, and can inhibit the increase of the permeability of the intestinal tract caused by ulcerative colitis. According to the application, the treatment effect of the five-membered heterocycle substituted styrene derivative on ulcerative colitis and the improvement effect on the intestinal barrier function are defined from the action mechanism, and the activation of an aromatic receptor can also improve the intestinal immune function; the invention provides a new therapeutic target and theoretical basis for fundamental research and clinical treatment of ulcerative colitis.

The application provides a lactobacillus plantarum DX7 and a method and application thereof for producing indole lactic acid, relates to the field of food microbial technology, and the lactobacillus plantarum DX7 has been preserved in the Guangdong Microbial Culture Collection Center on June 12, 2025, and the preservation number is GDMCC NO.66498. The lactobacillus plantarum DX7 in the application is significantly activated under the stimulation of deep-line walnut inner seed coat polyphenol, and can efficiently convert tryptophan into ILA. Experimental results show that the ILA yield of the strain reaches 217.56 mu g / mL. Moreover, the strain and deep-line walnut inner seed coat polyphenol can significantly relieve the colon inflammation symptoms of a DSS-induced colon inflammation mouse by gavage. The application not only provides a new strategy for efficient biological preparation of the functional component ILA, but also provides a basis and potential solution for dietary intervention of inflammatory bowel disease.